Key Highlights

  • Loss per share was USD 0.63 against an estimate of a USD 0.60 loss.
  • Net loss was USD 49.97 million, against USD 30.28 million a year earlier.
  • Research and development expenses were USD 53.70 million, against USD 28.99 million.
  • Cash and marketable securities were USD 1.2 billion at September 30.

Oruka Therapeutics (NASDAQ:ORKA) reported a third quarter 2026 loss per share of USD 0.63, against an estimate of a USD 0.60 loss and a USD 0.55 loss in the third quarter of 2025. Net loss was USD 49.97 million, compared with USD 30.28 million in the prior-year quarter.

The loss from operations was USD 62.14 million, against USD 34.11 million. The company reported the figures in its quarterly filing for the period ended September 30, 2026.

Operating Expenses

Research and development expenses were USD 53.70 million, compared with USD 28.99 million. General and administrative expenses were USD 8.44 million, compared with USD 5.12 million. Total operating expenses were USD 62.14 million, against USD 34.11 million.

The filing says other Research and Development expenses increased by USD 0.6 million to USD 1.9 million, primarily due to a higher allocation of shared costs to support increased research and development headcount. Stock-based compensation expense increased by USD 2.6 million to USD 4.4 million, primarily due to additional Equity awards to existing employees and new hires. Other general and administrative expenses decreased by USD 0.2 million to USD 1.2 million.

Nine-Month Results

For the nine months ended September 30, 2026, net loss was USD 122.99 million, compared with USD 75.85 million, and loss per share was USD 1.67, against USD 1.40. Research and development expenses were USD 126.10 million, against USD 73.00 million, and general and administrative expenses were USD 22.58 million, against USD 14.62 million.

Total operating expenses for the nine months were USD 148.68 million, against USD 87.62 million.

Liquidity and Financing

As of September 30, 2026, the company had cash, cash equivalents and marketable securities of USD 1.2 billion, including cash and cash equivalents of USD 191.52 million and current marketable securities of USD 728.76 million. The company believes its existing cash, cash equivalents and marketable securities are sufficient to fund its operating plans for at least twelve months from the date of filing of the quarterly report.

Cash and cash equivalents were USD 191.52 million, compared with USD 46.94 million at the prior Balance Sheet date, and current marketable securities were USD 728.76 million, compared with USD 290.11 million. The filing also describes an accounting standards update that refines the scope exception for certain non-exchange-traded contracts with underlyings based on the operations or activities of one of the parties.

The filing describes an at-the-market sales agreement with TD Securities entered into on October 3, 2025, under which the company could issue and sell shares of common stock for aggregate gross proceeds of up to USD 200.0 million, and an amendment entered into on August 21, 2026.

Oruka Therapeutics Q3 2026 Earnings: Key Takeaways

Oruka Therapeutics reported a third quarter 2026 loss per share of USD 0.63 and a net loss of USD 49.97 million. Research and development expenses were USD 53.70 million, and cash, cash equivalents and marketable securities were USD 1.2 billion.